160 related articles for article (PubMed ID: 17761288)
1. Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.
Ditzel Santos D; Ho AW; Tournilhac O; Hatjiharissi E; Leleu X; Xu L; Tassone P; Neri P; Hunter ZR; Chemaly MA; Branagan AR; Manning RJ; Patterson CJ; Moreau AS; Ciccarelli B; Adamia S; Kriangkum J; Kutok JL; Tai YT; Zhang J; Pilarski LM; Anderson KC; Munshi N; Treon SP
Exp Hematol; 2007 Sep; 35(9):1366-75. PubMed ID: 17761288
[TBL] [Abstract][Full Text] [Related]
2. The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia.
Al-Katib AM; Mensah-Osman E; Aboukameel A; Mohammad R
Semin Oncol; 2003 Apr; 30(2):313-7. PubMed ID: 12720160
[TBL] [Abstract][Full Text] [Related]
3. Establishment of an animal model for Waldenström's macroglobulinemia.
Tsingotjidou AS; Emmanouilides CE; Siotou E; Poutahidis T; Xagorari A; Loukopoulos P; Sotiropoulos D; Bekiari C; Doulberis M; Givissis P; Fassas A; Anagnostopoulos A
Exp Hematol; 2009 Apr; 37(4):469-76. PubMed ID: 19302921
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotypic analysis of Waldenstrom's macroglobulinemia.
San Miguel JF; Vidriales MB; Ocio E; Mateo G; Sánchez-Guijo F; Sánchez ML; Escribano L; Bárez A; Moro MJ; Hernández J; Aguilera C; Cuello R; García-Frade J; López R; Portero J; Orfao A
Semin Oncol; 2003 Apr; 30(2):187-95. PubMed ID: 12720134
[TBL] [Abstract][Full Text] [Related]
5. Malignant hematopoietic cell lines: in vitro models for the study of Waldenström's macroglobulinemia.
Drexler HG; MacLeod RA
Leuk Res; 2008 Nov; 32(11):1669-73. PubMed ID: 18533260
[TBL] [Abstract][Full Text] [Related]
6. A SCID-hu in vivo model of human Waldenström macroglobulinemia.
Tassone P; Neri P; Kutok JL; Tournilhac O; Santos DD; Hatjiharissi E; Munshi V; Venuta S; Anderson KC; Treon SP; Munshi NC
Blood; 2005 Aug; 106(4):1341-5. PubMed ID: 15886318
[TBL] [Abstract][Full Text] [Related]
7. Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells.
Remstein ED; Hanson CA; Kyle RA; Hodnefield JM; Kurtin PJ
Semin Oncol; 2003 Apr; 30(2):182-6. PubMed ID: 12720133
[TBL] [Abstract][Full Text] [Related]
8. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
Treon SP; Kelliher A; Keele B; Frankel S; Emmanouilides C; Kimby E; Schlossman R; Mitsiades N; Mitsiades C; Preffer F; Anderson KC
Semin Oncol; 2003 Apr; 30(2):248-52. PubMed ID: 12720146
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.
Mohammad RM; al-Katib A; Pettit GR; Sensenbrenner LL
Cancer Res; 1994 Jan; 54(1):165-8. PubMed ID: 8261437
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27.
Zhou Y; Liu X; Xu L; Tseng H; Cao Y; Jiang J; Ciccarelli BT; Yang G; Patterson CJ; Hunter ZR; Treon SP
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):172-5. PubMed ID: 21856553
[TBL] [Abstract][Full Text] [Related]
12. Developing diagnostic criteria in Waldenstrom's macroglobulinemia.
Owen RG
Semin Oncol; 2003 Apr; 30(2):196-200. PubMed ID: 12720135
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
Konoplev S; Medeiros LJ; Bueso-Ramos CE; Jorgensen JL; Lin P
Am J Clin Pathol; 2005 Sep; 124(3):414-20. PubMed ID: 16191510
[TBL] [Abstract][Full Text] [Related]
14. CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia.
Hunter ZR; Branagan AR; Manning R; Patterson CJ; Santos DD; Tournilhac O; Dorfman DM; Treon SP
Clin Lymphoma; 2005 Mar; 5(4):246-9. PubMed ID: 15794857
[TBL] [Abstract][Full Text] [Related]
15. [Complete response achieved after rituximab plus CHOP therapy in a patient with rapidly progressing Waldenstrom's macroglobulinemia].
Ise M; Sakai C; Kumagai K
Rinsho Ketsueki; 2009 Jan; 50(1):34-8. PubMed ID: 19225227
[TBL] [Abstract][Full Text] [Related]
16. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.
Ho AW; Hatjiharissi E; Ciccarelli BT; Branagan AR; Hunter ZR; Leleu X; Tournilhac O; Xu L; O'Connor K; Manning RJ; Santos DD; Chemaly M; Patterson CJ; Soumerai JD; Munshi NC; McEarchern JA; Law CL; Grewal IS; Treon SP
Blood; 2008 Dec; 112(12):4683-9. PubMed ID: 18216294
[TBL] [Abstract][Full Text] [Related]
17. 14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia.
Avet-Loiseau H; Garand R; Lodé L; Robillard N; Bataille R
Semin Oncol; 2003 Apr; 30(2):153-5. PubMed ID: 12720126
[TBL] [Abstract][Full Text] [Related]
18. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
Santos DD; Hatjiharissi E; Tournilhac O; Chemaly MZ; Leleu X; Xu L; Patterson C; Branagan AR; Manning RJ; Ho AW; Hunter ZR; Dimmock EA; Kutok JL; Churchill WH; Castells MC; Tai YT; Anderson KC; Treon SP
Clin Lymphoma Myeloma; 2006 May; 6(6):478-83. PubMed ID: 16796779
[TBL] [Abstract][Full Text] [Related]
19. The malignant clone in Waldenstrom's macroglobulinemia.
Kriangkum J; Taylor BJ; Mant MJ; Treon SP; Belch AR; Pilarski LM
Semin Oncol; 2003 Apr; 30(2):132-5. PubMed ID: 12720122
[TBL] [Abstract][Full Text] [Related]
20. Propagation of Waldenström's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model.
al-Katib A; Mohammad R; Hamdan M; Mohamed AN; Dan M; Smith MR
Blood; 1993 Jun; 81(11):3034-42. PubMed ID: 8499639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
